Slingshot members are tracking this event:

England's National Institute for Health and Care Excellence (NICE) Recommends Celgene's (CELG) Otezla for Approval to Treat Adult Patients with Active Psoriatic Arthritis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nice, Otezla, Adult Patients, Active Psoriatic Arthritis